Diligence memo · auto-generated · as of July 2, 2026
Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Aralez Pharmaceuticals Inc. operates in Pharmaceuticals, based in Vancouver.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aralez Pharmaceuticals Inc. has raised $75M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $75M on 2016-02-05.
Most recent recorded round closed around 2016-02-05.
Valuation (modeled)modeled
Provath models Aralez Pharmaceuticals Inc. at approximately $2.6B (range $244M–$6.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.13× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era. Within the normal band (113% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 10.4 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 87% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Amplyx Pharmaceuticals, Inc., Ligand Pharmaceuticals Inc, Homology Medicines, Inc., KSQ Therapeutics, Inc., TP Therapeutics, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.